ClinicalTrials.gg
RecruitingNCT07402707DOSAGEUpdated Apr 23, 2026

Dosing of Steroids for Acute Asthma Given in the Emergency Department - a Pilot Randomised Feasibility Trial of Dexamethasone in Children

A Phase 4 interventional study of dexamethasone oral in Acute Asthma and Dexamethasone, sponsored by Sheffield Children's NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 4 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Sheffield Children's NHS Foundation Trust · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
4 Years to 15 Years
Sex
All
01

Study summary

Steroids given by mouth are an important first line treatment for children presenting with asthma attacks. Dexamethasone is the steroid used in some emergency departments (EDs) because of the need for a single dose and as it is well tolerated. The dose of dexamethasone in treating asthma attacks is not clearly established. This study compares two different doses of dexamethasone in children presenting with an asthma attack. Investigators will compare the effect of two different doses in reducing the need for a repeat prescription of steroids for an asthma attack in the 2 weeks after the first treatment. The investigators will also look at how often children attend the ED or their GP after being given treatment as well as the acceptability to parents and children. Although this study may provide an answer to the question of whether the different doses have the same effect, the investigators believe that a larger study will be needed to provide robust generalisable evidence, as well as to ensure that the outcomes are truly what matters to parents, children and healthcare professionals. This study will provide valuable information to enable a larger study to be undertaken.

Read the detailed description

Asthma is the most common chronic condition to affect children, with approximately 1.1 million children treated for asthma in the UK. Hospital episode statistics confirm that emergency department (ED) attendances for exacerbations of asthma have risen over the past year, and accounts for a significant number of ED attendances and hospital admissions. Nearly 1000 children attended the ED at Sheffield Children's Hospital for asthma in 2022-23, with almost half requiring admission.

Steroids/glucocorticoids are first line treatments for acute exacerbations of asthma. The anti-inflammatory action of steroids reduces the airway oedema and secretions associated with acute asthma exacerbations, and their effects may be noted within two to four hours of administration. Traditionally, oral prednisolone has been the treatment used most widely. Prednisolone given orally is often vomited by the child and needs to be taken for 3-5 days. Dexamethasone is an alternative steroid which is better tolerated and due to its long duration of action can be used as a single dose given in the ED. Studies comparing prednisolone and Dexamethasone have demonstrated that Dexamethasone is non-inferior to Prednisolone in the treatment of asthma exacerbations (1,2). A systematic review found no differences between the two steroids in terms of hospital admission rates, time spent in the ED or relapse events, however children receiving Dexamethasone experienced lower noncompliance and vomiting rates. (3) Practically, use of dexamethasone allows simplification of treatment in EDs and improves flow as children do not have to wait for discharge medication. Treatment with Dexamethasone is more cost effective and treatment adherence is better.

In a survey of 37 UK EDs undertaken by the study team, 19 departments currently use Prednisolone, and 18 use Dexamethasone. Of the latter, 7 use 600 micrograms/kg and the other 11 use 300 micrograms/kg. The currently used dose at our institution is 600 micrograms/kg. The dose of dexamethasone used as oral treatment for exacerbations of asthma is not well established, as demonstrated by the survey and this reflects the studies which sought to compare Prednisolone with Dexamethasone which used different doses and routes. (4-6) While systemic steroids are an effective and safe treatment, there is a dose-dependent profile of side effects, hence the lowest effective dose should be used. This is even more important given concerns over side effects from even shorter courses of steroids as used in asthma (7). Dexamethasone is well established in the treatment of other acute paediatric respiratory conditions, such as croup, with evidence demonstrating that lower doses (150micrograms/kg) are safer, and equally as effective as higher doses (600 micrograms/kg) in this condition. (8, 9) The investigators hypothesise that using a lower dose of Dexamethasone (300 micrograms/kg) is not inferior to the 600 microgram/kg dose in the treatment of acute asthma. The effectiveness of treatment can be measured as length of stay in hospital or time to improvement in respiratory distress severity scores, however both of these can be subjective. Need for re-treatment with steroids is a pragmatic surrogate of efficacy of treatments as well as the need for further unscheduled medical care in children with asthma exacerbations. In our patient and parent involvement work for this study, parents have agreed that this outcome is important. They also want to be reassured that an effective dose is being given but are supportive of the study's objective and think it an important research question.

The investigators hypothesise that children treated with either dose of dexamethasone have a similar rate of retreatment with oral steroids (dexamethasone or prednisolone) for their asthma exacerbation.

02

Conditions studied

  • Acute Asthma
  • Dexamethasone

Browse trials for

Keywords

  • Dexamethasone
03

In context

Asthma

4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.

This study's planned enrollment of 104 is above the median of 78 across 3,341 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Sheffield Children's NHS Foundation Trust is the lead sponsor of 53 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 4-15 years (inclusive) presenting to the ED with an asthma exacerbation, where oral are recommended by Trust/National guidelines.
  • Children whose parents/carers do not speak English will also be eligible provided they speak one of the common languages where an interpreter and Information Sheets are available (Slovakian, Arabic and Urdu).

Exclusion criteria

Exclusion Criteria:

  • Children who have been treated with oral or IV in the last 2 weeks.
  • to the study drug.
  • Children who have concomitant stridor.
  • First episode of wheezing (not previously diagnosed as asthma).
  • Children with known difficult asthma who receive longer courses of steroids as standard.
  • Life threatening episode of asthma.
  • Children with other conditions that require them to have steroids when unwell.
  • Children who are involved in current research or have recently been involved in research prior to recruitment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Other
    0.3mg dose

    Lower dose of dexamethasone

    Drug: dexamethasone oral

  • Other
    0.6mg

    Lower dose of dexamethasone

    Drug: dexamethasone oral

Interventions

06

What researchers measure

Primary outcomes

  1. Participant recruitment

    The primary outcomes will be recruitment rate and time, attrition, willingness to be randomised, completion and follow-up rates

    Time frame: 7 months

Secondary outcomes

  1. Tolerability

    Secondary outcomes of tolerability, mean abbreviated Asthma Control Test (ACT)

    Time frame: 7 months

  2. Tolerability

    Asthma Control Questionnaire (ACQ) scores,

    Time frame: 7 months

  3. Tolerability

    Reliever (Salbutamol) use

    Time frame: 7 months

  4. Tolerability

    Need for repeat steroid prescription

    Time frame: 7 months

  5. Hospital Admission

    Hospital admission, length of stay and unscheduled return visits to a health care practitioner within 14 days.

    Time frame: 7 months

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07402707
Lead sponsor
Sheffield Children's NHS Foundation Trust
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Feb 23, 2026
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Apr 23, 2026

Study contacts

Meena Balasubramanian
Contact
meena.balasubramanian@nhs.net
0114 3053136
Gillian Gatenby
Contact
gillian.gatenby@nhs.net
0114 3053136
Judith Gilchrist
principal investigator · Sheffield Children's NHS Foundation Trust

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion